KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $1.4 billion.

  • NovoCure's Liabilities and Shareholders Equity rose 1139.19% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 billion, marking a year-over-year increase of 840.01%. This contributed to the annual value of $1.2 billion for FY2024, which is 825.87% up from last year.
  • Latest data reveals that NovoCure reported Liabilities and Shareholders Equity of $1.4 billion as of Q3 2025, which was up 1139.19% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, NovoCure's Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q3 2025 and a low of $1.1 billion during Q1 2021
  • For the 5-year period, NovoCure's Liabilities and Shareholders Equity averaged around $1.2 billion, with its median value being $1.2 billion (2022).
  • As far as peak fluctuations go, NovoCure's Liabilities and Shareholders Equity skyrocketed by 15993.63% in 2021, and later plummeted by 450.56% in 2024.
  • Over the past 5 years, NovoCure's Liabilities and Shareholders Equity (Quarter) stood at $1.1 billion in 2021, then grew by 4.58% to $1.2 billion in 2022, then dropped by 3.82% to $1.1 billion in 2023, then grew by 8.26% to $1.2 billion in 2024, then grew by 9.7% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.2 billion during Q1 2025.